Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus

Cellular Immunology

Volumn 276, Issue 1-2, 2012, Pages 42-51

  Al Gadban, Mohammed M ^a   German, Jashalynn ^b   Truman, Jean Philip ^a   Soodavar, Farzan ^a   Riemer, Ellen C ^a   Twal, Waleed O ^a   Smith, Kent J ^a   Heller, Demarcus ^b   Hofbauer, Ann F ^a,c   Oates, Jim C ^a,c   Hammad, Samar M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Ceramide; Lupus; Nitric oxide synthase; Oxidized LDL; Sphingosine 1 phosphate; Sphingosine kinase

Indexed keywords

CERAMIDE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TRIACYLGLYCEROL;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE DELETION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID STORAGE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ANIMALS; AORTA; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; SPHINGOLIPIDS;

MUS;

EID: 84863865053     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.03.007     Document Type: Article

References (81)

1. Lopez-Pedrera C., Aguirre M.A., Barbarroja N., Cuadrado M.J. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J. Biomed. Biotechnol. 2010.
2. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112:3337-3347.
3. Elliott J.R., Manzi S., Edmundowicz D. The role of preventive cardiology in systemic lupus erythematosus. Curr. Rheumatol. Rep. 2007, 9:125-130.
4. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 1997, 145:408-415.
5. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
6. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
7. Alexanderson E., Ochoa J.M., Calleja R., Juarez-Rojas J.G., Prior J.O., Jacome R., et al. Endothelial dysfunction in systemic lupus erythematosus evaluation with 13N-ammonia PET. J. Nucl. Med. 2010, 51:1927-1931.
8. Lerman A., Burnett J.C. Intact and altered endothelium in regulation of vasomotion. Circulation 1992, 86(6 Suppl):III12-9.
9. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler., Thromb., Vasc. Biol. 2003, 23:168-175.
10. Anderson T.J. Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol. 1999, 34:631-638.
11. El-Magadmi M., Bodill H., Ahmad Y., Durrington P.N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110:399-404.
12. Rao K.M. Molecular mechanisms regulating iNOS expression in various cell types. J. Toxicol. Environ. Health B 2000, 3:27-58.
13. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 1996, 20:707-727.
14. Freeman B.A., White C.R., Gutierrez H., Paler-Martinez A., Tarpey M.M., Rubbo H. Oxygen radical-nitric oxide reactions in vascular diseases. Adv. Pharmacol. 1995, 34:45-69.
15. Oates J.C., Gilkeson G.S. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin. Immunol. 2006, 121:243-250.
16. Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 1990, 30:535-560.
17. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle?. Circulation 1997, 95:1101-1103.
18. Tsutsui M., Shimokawa H., Otsuji Y., Ueta Y., Sasaguri Y., Yanagihara N. Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice. Circ. J. 2009, 73:986-993.
19. Bulotta S., Barsacchi R., Rotiroti D., Borgese N., Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J. Biol. Chem. 2001, 276:6529-6536.
20. Sciorati C., Rovere P., Ferrarini M., Heltai S., Manfredi A.A., Clementi E. Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes. J. Biol. Chem. 1997, 272:23211-23215.
21. Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science 1996, 274:1855-1859.
22. Spiegel S., Merrill A.H. Sphingolipid metabolism and cell growth regulation. FASEB J. 1996, 10:1388-1397.
23. Thompson K.C., Trowern A., Fowell A., Marathe M., Haycock C., Arthur M.J., et al. Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatology 1998, 28:1518-1524.
24. Mathias S., Pena L.A., Kolesnick R.N. Signal transduction of stress via ceramide. Biochem J. 1998, 335(Pt 3):465-480.
25. Njoku C., Self S.E., Ruiz P., Hofbauer A.F., Gilkeson G.S., Oates J.C. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J. Investig. Med. 2008, 56:911-919.
26. Hammad S.M., Pierce J.S., Soodavar F., Smith K.J., Al Gadban M.M., Rembiesa B., et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. 2010, 51:3074-3087.
27. Iacobini C., Menini S., Ricci C., Scipioni A., Sansoni V., Cordone S., et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice. Role of lipoxidation via receptor-mediated mechanisms. Arterioscler. Thromb. Vasc. Biol. 2009, 29:831-836.
28. Hammad S.M., Taha T.A., Nareika A., Johnson K.R., Lopes-Virella M.F., Obeid L.M. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat. 2006, 79:126-140.
29. Qiao J.H., Castellani L.W., Fishbein M.C., Lusis A.J. Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler. Thromb. 1993, 13:932-943.
30. Ichi I., Takashima Y., Adachi N., Nakahara K., Kamikawa C., Harada-Shiba M., et al. Effects of dietary cholesterol on tissue ceramides and oxidation products of apolipoprotein B-100 in ApoE-deficient mice. Lipids 2007, 42:893-900.
31. Naz S.M., Symmons D.P. Mortality in established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007, 21:871-883.
32. Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997, 6:533-539.
33. Svenungsson E., Gunnarsson I., Fei G.Z., Lundberg I.E., Klareskog L., Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003, 48:2533-2540.
34. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006, 54:2541-2549.
35. Hahn B.H., Grossman J., Ansell B.J., Skaggs B.J., McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 2008, 10:213.
36. Juarez-Rojas J., Medina-Urrutia A., Posadas-Sanchez R., Jorge-Galarza E., Mendoza-Perez E., Caracas-Portilla N., et al. High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus. Lupus 2008, 17:981-987.
37. Hammad S.M., Powell-Braxton L., Otvos J.D., Eldridge L., Won W., Lyons T.J. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 2003, 52:916-921.
38. Hammad S.M. Blood sphingolipids in homeostasis and pathobiology. Adv. Exp. Med. Biol. 2011, 721:57-66.
39. Mashmoushi A.K., Gilkeson G.S., Oates J.C. The role of reactive nitrogen and oxygen intermediates in systemic lupus erythematosus. Systemic Lupus Erythematosus 2011, 199-211. Elsevier Inc. R. Lahita (Ed.).
40. Won J.S., Singh I. Sphingolipid signaling and redox regulation. Free Radic. Biol. Med. 2006, 40:1875-1888.
41. Huwiler A., Pfeilschifter J., van den Bosch H. Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells. J. Biol. Chem. 1999, 274:7190-7195.
42. Sanvicens N., Cotter T.G. Ceramide is the key mediator of oxidative stress-induced apoptosis in retinal photoreceptor cells. J. Neurochem. 2006, 98:1432-1444.
43. Schutze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced " acidic" sphingomyelin breakdown. Cell 1992, 71:765-776.
44. Truman J-P., Al Gadban M.M., Smith K.J., Hammad S.M. Acid sphingomyelinase in macrophage biology. Cell Mol. Life Sci. 2011, 68:3293-3305.
45. Hammad S.M., Crellin H.G., Wu B.X., Melton J., Anelli V., Obeid L.M. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid Mediat. 2008, 85:107-114.
46. F. Roviezzo, V. Brancaleone, L. De Gruttola, V. Vellecco, M. Bucci, B. D'Agostino, et al., Sphingosine-1-phosphate modulates vascular permeability and cell recruitment in acute inflammation in vivo, J. Pharmacol. Exp. Ther. 337 (2011) 830-837.
47. Boswell J.M., Yui M.A., Burt D.W., Kelley V.E. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 1988, 141:3050-3054.
48. Maury C.P., Teppo A.M. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum. 1989, 32:146-150.
49. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006, 54:2541-2549.
50. Viallard J.F., Pellegrin J.L., Ranchin V., Schaeverbeke T., Dehais J., Longy-Boursier M., et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 1999, 115:189-195.
51. Wong C.K., Ho C.Y., Li E.K., Lam C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9:589-593.
52. Wuthrich R.P., Jevnikar A.M., Takei F., Glimcher L.H., Kelley V.E. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am. J. Pathol. 1990, 136:441-450.
53. Chun H.Y., Chung J.W., Kim H.A., Yun J.M., Jeon J.Y., Ye Y.M., et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007, 27:461-466.
54. Liu Y., Zhu T., Cai G., Qin Y., Wang W., Tang G., et al. Elevated circulating CD4+ ICOS+ Foxp3+ T cells contribute to overproduction of IL-10 and are correlated with disease severity in patients with systemic lupus erythematosus. Lupus 2011, 20:620-627.
55. Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 1999, 85:e17-e24.
56. Jimenez Mdel P., Walls L., Fierer J. High levels of interleukin-10 impair resistance to pulmonary coccidioidomycosis in mice in part through control of nitric oxide synthase 2 expression. Infect. Immun. 2006, 74:3387-3395.
57. Cattaruzza M., Slodowski W., Stojakovic M., Krzesz R., Hecker M. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J. Biol. Chem. 2003, 278:37874-37880.
58. Dhingra S., Sharma A.K., Singla D.K., Singal P.K. P38 and ERK1/2 MAPKs mediate the interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3524-H3531.
59. Song S., Ling-Hu H., Roebuck K.A., Rabbi M.F., Donnelly R.P., Finnegan A. Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes. Blood 1997, 89:4461-4469.
60. Yin Z., Bahtiyar G., Zhang N., Liu L., Zhu P., Robert M.E., et al. IL-10 regulates murine lupus. J. immunol. 2002, 169:2148-2155.
61. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43:1790-1800.
62. Bauer H., Jung T., Tsikas D., Stichtenoth D.O., Frolich J.C., Neumann C. Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells. Immunology 1997, 90:205-211.
63. Gonzalez-Leon M.C., Soares-Schanoski A., del Fresno C., Cimadevila A., Gomez-Pina V., Mendoza-Barbera E., et al. Nitric oxide induces SOCS-1 expression in human monocytes in a TNF-alpha-dependent manner. J. Endotoxin Res. 2006, 12:296-306.
64. Benbernou N., Esnault S., Shin H.C., Fekkar H., Guenounou M. Differential regulation of IFN-gamma, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway. Immunology 1997, 91:361-368.
65. Blain H., Abdelmouttaleb I., Belmin J., Blain A., Floquet J., Gueant J.L., et al. Arterial wall production of cytokines in giant cell arteritis: results of a pilot study using human temporal artery cultures. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:M241-M245.
66. Brack A., Geisler A., Martinez-Taboada V.M., Younge B.R., Goronzy J.J., Weyand C.M. Giant cell vasculitis is a T cell-dependent disease. Mol. Med. 1997, 3:530-543.
67. Wagner A.D., Bjornsson J., Bartley G.B., Goronzy J.J., Weyand C.M. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am. J. Pathol. 1996, 148:1925-1933.
68. Kaiser M., Younge B., Bjornsson J., Goronzy J.J., Weyand C.M. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am. J. Pathol. 1999, 155:765-774.
69. Weyand C.M., Tetzlaff N., Bjornsson J., Brack A., Younge B., Goronzy J.J. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum. 1997, 40:19-26.
70. Hammad S.M., Twal W.O., Barth J.L., Smith K.J., Saad A.F., Virella G., et al. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 2009, 202:394-404.
71. Al Gadban M.M., Smith K.J., Soodavar F., Piansay C., Chassereau C., Twal W.O., et al. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One 2010, 5.
72. Jenkins S.J., Ruckerl D., Cook P.C., Jones L.H., Finkelman F.D., van Rooijen N., et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011, 332:1284-1288.
73. Schwartz C.J., Mitchell J.R. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation 1962, 26:73-78.
74. Ramshaw A.L., Parums D.V. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. Histopathology 1990, 17:543-552.
75. Khan S.A., Lee K., Minhas K.M., Gonzalez D.R., Raju S.V., Tejani A.D., et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc. Natl Acad. Sci. USA 2004, 101:15944-15948.
76. Mihm M.J., Coyle C.M., Jing L., Bauer J.A. Vascular peroxynitrite formation during organic nitrate tolerance. J. Pharmacol. Exp. Ther. 1999, 291:194-198.
77. Beckman J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 1996, 9:836-844.
78. Schwalm S., Pfeilschifter J., Huwiler A. Sphingosine kinase 1 is critically involved in nitric oxide-mediated human endothelial cell migration and tube formation. Br. J. Pharmacol. 2010, 160:1641-1651.
79. Florio T., Arena S., Pattarozzi A., Thellung S., Corsaro A., Villa V., et al. Basic fibroblast growth factor activates endothelial nitric-oxide synthase in CHO-K1 cells via the activation of ceramide synthesis. Mol. Pharmacol. 2003, 63:297-310.
80. Okazaki H., Hirata D., Kamimura T., Sato H., Iwamoto M., Yoshio T., et al. Effects of FTY720 in MRL-lpr/lpr mice. Therapeutic potential in systemic lupus erythematosus. J. Rheumatol. 2002, 29:707-716.
81. Ando S., Amano H., Amano E., Minowa K., Watanabe T., Nakano S., et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem. Biophys. Res. Commun. 2010, 394:804-810.